$BIOLQ
BIOLASE, INC

2020 Q3 Form 10-Q Financial Statement

#000156459020053929 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $6.539M $8.646M $8.645M
YoY Change -24.37% -20.94% -28.87%
Cost Of Revenue $4.265M $5.677M $5.265M
YoY Change -24.87% -18.84% -32.93%
Gross Profit $2.274M $2.969M $3.380M
YoY Change -23.41% -24.66% -21.58%
Gross Profit Margin 34.78% 34.34% 39.1%
Selling, General & Admin $4.978M $6.725M $5.783M
YoY Change -25.98% -6.21% -24.21%
% of Gross Profit 218.91% 226.51% 171.09%
Research & Development $963.0K $1.126M $1.124M
YoY Change -14.48% -12.03% -17.35%
% of Gross Profit 42.35% 37.93% 33.25%
Depreciation & Amortization $40.00K $220.0K $270.0K
YoY Change -81.82% 10.0% 8.0%
% of Gross Profit 1.76% 7.41% 7.99%
Operating Expenses $5.941M $7.851M $6.717M
YoY Change -24.33% -7.09% -25.2%
Operating Profit -$3.667M -$4.882M -$3.337M
YoY Change -24.89% 8.27% -28.54%
Interest Expense $568.0K -$551.0K -$529.0K
YoY Change -203.09% 400.91% 140.45%
% of Operating Profit
Other Income/Expense, Net $3.694M -$570.0K -$534.0K
YoY Change -748.07%
Pretax Income $27.00K -$5.452M -$3.871M
YoY Change -100.5% 18.11% -21.0%
Income Tax -$15.00K $26.00K $28.00K
% Of Pretax Income -55.56%
Net Earnings $12.00K -$5.478M -$3.899M
YoY Change -100.22% 17.3% -20.59%
Net Earnings / Revenue 0.18% -63.36% -45.1%
Basic Earnings Per Share -$0.21 -$0.25
Diluted Earnings Per Share -$0.21 -$0.25 -$172.5K
COMMON SHARES
Basic Shares Outstanding 81.34M 21.90M
Diluted Shares Outstanding 81.34M 21.90M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.85M $2.090M $3.720M
YoY Change 801.91% -6.7% 28.28%
Cash & Equivalents $19.16M $2.091M $3.720M
Short-Term Investments
Other Short-Term Assets $1.210M $1.190M $1.260M
YoY Change 1.68% 22.68% -31.89%
Inventory $12.59M $11.54M $12.33M
Prepaid Expenses
Receivables $3.390M $8.474M $9.740M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $36.05M $23.29M $27.06M
YoY Change 54.79% -16.91% -7.21%
LONG-TERM ASSETS
Property, Plant & Equipment $2.800M $1.340M $1.585M
YoY Change 108.96% -54.27% -49.84%
Goodwill $2.926M $2.926M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $220.0K $718.0K $793.0K
YoY Change -69.36% 94.05% 98.25%
Total Long-Term Assets $5.946M $4.984M $5.304M
YoY Change 19.3% -20.0% -18.27%
TOTAL ASSETS
Total Short-Term Assets $36.05M $23.29M $27.06M
Total Long-Term Assets $5.946M $4.984M $5.304M
Total Assets $42.00M $28.27M $32.36M
YoY Change 48.54% -17.48% -9.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.592M $6.604M $5.878M
YoY Change -60.75% -12.76% -15.18%
Accrued Expenses $4.279M $4.950M $4.899M
YoY Change -13.56% 4.21% 7.91%
Deferred Revenue $1.616M $2.512M $2.513M
YoY Change -35.67% 11.0% 13.61%
Short-Term Debt $12.95M $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $12.95M
YoY Change
Total Short-Term Liabilities $21.43M $14.07M $13.29M
YoY Change 52.37% -18.46% -9.78%
LONG-TERM LIABILITIES
Long-Term Debt $3.140M $13.36M $13.33M
YoY Change -76.49% 26612.0% 16560.0%
Other Long-Term Liabilities $1.097M $1.145M $1.880M
YoY Change -4.19% 124.51% 452.94%
Total Long-Term Liabilities $4.237M $14.50M $13.33M
YoY Change -70.78% 2489.46% 3073.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.43M $14.07M $13.29M
Total Long-Term Liabilities $4.237M $14.50M $13.33M
Total Liabilities $28.15M $29.34M $28.57M
YoY Change -4.07% 63.72% 87.22%
SHAREHOLDERS EQUITY
Retained Earnings -$245.2M -$231.0M -$225.5M
YoY Change 6.18%
Common Stock $259.4M $230.7M $230.0M
YoY Change 12.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.85M -$1.066M $3.800M
YoY Change
Total Liabilities & Shareholders Equity $42.00M $28.27M $32.36M
YoY Change 48.54% -17.48% -9.22%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $12.00K -$5.478M -$3.899M
YoY Change -100.22% 17.3% -20.59%
Depreciation, Depletion And Amortization $40.00K $220.0K $270.0K
YoY Change -81.82% 10.0% 8.0%
Cash From Operating Activities -$2.110M -$1.440M -$1.600M
YoY Change 46.53% -35.71% -55.43%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$120.0K
YoY Change -100.0% 1100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$120.0K
YoY Change -100.0% -125.0% 1100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.39M -50.00K 2.470M
YoY Change -30880.0% -103.33% -230.69%
NET CHANGE
Cash From Operating Activities -2.110M -1.440M -1.600M
Cash From Investing Activities 0.000 -10.00K -120.0K
Cash From Financing Activities 15.39M -50.00K 2.470M
Net Change In Cash 13.28M -1.500M 750.0K
YoY Change -985.33% 114.29% -113.66%
FREE CASH FLOW
Cash From Operating Activities -$2.110M -$1.440M -$1.600M
Capital Expenditures $0.00 -$10.00K -$120.0K
Free Cash Flow -$2.110M -$1.430M -$1.480M
YoY Change 47.55% -36.16% -58.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019Q4 us-gaap Inventory Net
InventoryNet
10995000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5332000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4279000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1859000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1097000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1119000
CY2019Q4 us-gaap Liabilities
Liabilities
27505000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
3965000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
141000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
93000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
259385000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235594000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-534000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-701000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245234000
dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
us-gaap Operating Income Loss
OperatingIncomeLoss
-12573000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-68000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-68000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2019Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
245000
CY2020Q3 us-gaap Assets
Assets
41996000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
27019000
CY2020Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1616000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1193000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2237000
CY2019Q4 us-gaap Goodwill
Goodwill
2926000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
276000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
12946000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
433000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13466000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4744000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21433000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25779000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
358000
CY2020Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
412000
CY2020Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
204000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q3 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
3140000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5789000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8760000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1163000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2061000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
220000
CY2019Q4 us-gaap Assets
Assets
31847000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2592000
CY2020Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
4209000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3694000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-570000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
513000
CY2020Q3 us-gaap Liabilities
Liabilities
28145000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3000000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1126000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8114000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
963000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2644000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93044000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31439000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92999000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31439000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6539000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8646000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14260000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27617000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234547000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
13851000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
377000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41996000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31847000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3837000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2531000
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
70000
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
70000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
4265000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
5677000
us-gaap Cost Of Revenue
CostOfRevenue
9692000
us-gaap Cost Of Revenue
CostOfRevenue
17746000
CY2020Q3 us-gaap Gross Profit
GrossProfit
2274000
CY2019Q3 us-gaap Gross Profit
GrossProfit
2969000
us-gaap Gross Profit
GrossProfit
4568000
us-gaap Gross Profit
GrossProfit
9871000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2678000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3515000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7475000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10665000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2300000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3210000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7446000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
3800000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
659000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3665000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
5941000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
7851000
us-gaap Operating Expenses
OperatingExpenses
17565000
us-gaap Operating Expenses
OperatingExpenses
22444000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3667000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4882000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12997000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
53000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-19000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-568000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-551000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1782000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1559000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
4209000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2359000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1627000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5452000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10638000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14200000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
68000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
12000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5478000
us-gaap Net Income Loss
NetIncomeLoss
-10687000
us-gaap Net Income Loss
NetIncomeLoss
-14268000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
111000
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
167000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-170000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
123000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5606000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10520000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14438000
CY2020Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
17378000
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
17378000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17366000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5478000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28065000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14268000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81341000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21898000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50366000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21545000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81341000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
856000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
67000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1846000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
161000
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
81000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-1066000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11089000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1835000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
236000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21898000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50366000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21545000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1309000
CY2020Q3 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
46000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3872000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
209000
us-gaap Profit Loss
ProfitLoss
-10687000
us-gaap Profit Loss
ProfitLoss
-14268000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
527000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
754000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
46000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1263000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1243000
biol Provision For Sales Returns
ProvisionForSalesReturns
87000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
103000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
240000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
130000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5850000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
123000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1640000
biol Earned Interest Income
EarnedInterestIncome
-2000
us-gaap Share Based Compensation
ShareBasedCompensation
2367000
us-gaap Share Based Compensation
ShareBasedCompensation
1974000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4017000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1393000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1597000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-711000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-430000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1011000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3445000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1157000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-562000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
36000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11447000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8074000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
138000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-138000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6912000
biol Proceeds From Sale Of Preferred Stock
ProceedsFromSaleOfPreferredStock
2700000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
15300000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1281000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
50000
biol Payments Of Warrant Issuance Costs In Financing Activities
PaymentsOfWarrantIssuanceCostsInFinancingActivities
1640000
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
3140000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2500000
biol Principal Payment On Term Loan
PrincipalPaymentOnTermLoan
700000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3000000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
46000
biol Amount Paid For Debt Issuance Cost
AmountPaidForDebtIssuanceCost
75000
biol Amount Paid For Debt Issuance Cost
AmountPaidForDebtIssuanceCost
38000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24402000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2416000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
181000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-157000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13058000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5953000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6101000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8356000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19159000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2403000
us-gaap Interest Paid Net
InterestPaidNet
1438000
us-gaap Interest Paid Net
InterestPaidNet
1315000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
21000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
417000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
606000
biol Non Cash Accrual For Equity Offering Costs
NonCashAccrualForEquityOfferingCosts
191000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
151000
biol Non Cash Settlement Of Performance Award Liability
NonCashSettlementOfPerformanceAwardLiability
236000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
2037000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
824000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
17378000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
67000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
209000
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
24000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.<font style="font-weight:bold;color:#000000;"> </font></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and nine month periods ended September 30, 2020 and 2019, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.</p>
CY2020Q3 biol Aggregate Number Of Units Sold
AggregateNumberOfUnitsSold
18000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
45000000
CY2020Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16100000
CY2020Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.86
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.78
CY2019Q3 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.77
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.81
CY2020Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.14
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.22
CY2019Q3 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.23
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.19
CY2020Q3 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
487000
CY2019Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
559000
CY2020Q3 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1541000
CY2019Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2063000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2028000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2622000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
412000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
385000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1616000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2237000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
300000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
100000
CY2020Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
CY2019Q3 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
2400000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1900000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1400000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
847000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
770000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2367000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1974000
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.854
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.028
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.854
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0260
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0260
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1287000
biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
1241000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
124000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2404000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1060000
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
17000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.77
biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
0.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.35
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.19
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M4D
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
34000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
188000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
683000
CY2020Q2 biol Warrant Expiration Date
WarrantExpirationDate
2025-06-10
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6900000
CY2020Q2 biol Combined Purchase Price Per Share And Warrant
CombinedPurchasePricePerShareAndWarrant
0.64
CY2020Q2 biol Other Offering Expenses
OtherOfferingExpenses
700000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
67200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
67200000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5600000
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
4077000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3689000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1105000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1064000
CY2020Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7410000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6242000
CY2020Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1000000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1300000
CY2020Q3 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10138000
CY2019Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10353000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9566000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9322000
CY2020Q3 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
572000
CY2019Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1031000
CY2020Q3 us-gaap Land
Land
170000
CY2019Q4 us-gaap Land
Land
162000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2365000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1726000
CY2020Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
650000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
865000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
214000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
323000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
446000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2020Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
224000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
242000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
546000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
380000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
712000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
853000
CY2019Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1498000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1110000
CY2018Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1308000
CY2020Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
345000
CY2019Q3 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
523000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
575000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1145000
CY2020Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
344000
CY2019Q3 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
366000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
1807000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
1746000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfInterestInYearFour
1390000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
831000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
798000
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
854000
CY2019Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1655000
CY2019Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
701000
CY2019Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
954000
CY2020Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1354000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1534000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3140000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
3140000
CY2020Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
8000000
CY2020Q3 biol Line Of Credit Facility Covenant Unrestricted Cash Amount Deposited With Lenders
LineOfCreditFacilityCovenantUnrestrictedCashAmountDepositedWithLenders
1500000
CY2020Q2 biol Warrants Adjusted Exercise Price
WarrantsAdjustedExercisePrice
0.60
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5094000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2800000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
9409000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
137000
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17440000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
461000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearFive
1866000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
122000
CY2020Q3 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
7392000
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1278
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1225
us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
The Foothill Ranch lease is a 11,936 square foot lease and will be used as the Company’s headquarters upon commencement on July 1, 2020.
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
87000
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1440000
CY2020Q3 biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P4Y10M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
us-gaap Operating Lease Payments
OperatingLeasePayments
417000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2037000
biol Operating Lease Weighted Average Remaining Lease Terms
OperatingLeaseWeightedAverageRemainingLeaseTerms
P5Y2M12D
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
478000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
567000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
584000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
587000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
529000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
128000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2873000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
800000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2073000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
68000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
547000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
573000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
588000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
587000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
510000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2873000
CY2020Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2019Q3 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21

Files In Submission

Name View Source Status
0001564590-20-053929-index-headers.html Edgar Link pending
0001564590-20-053929-index.html Edgar Link pending
0001564590-20-053929.txt Edgar Link pending
0001564590-20-053929-xbrl.zip Edgar Link pending
biol-10q_20200930.htm Edgar Link pending
biol-20200930.xml Edgar Link completed
biol-20200930.xsd Edgar Link pending
biol-20200930_cal.xml Edgar Link unprocessable
biol-20200930_def.xml Edgar Link unprocessable
biol-20200930_lab.xml Edgar Link unprocessable
biol-20200930_pre.xml Edgar Link unprocessable
biol-ex311_10.htm Edgar Link pending
biol-ex312_13.htm Edgar Link pending
biol-ex321_15.htm Edgar Link pending
biol-ex322_11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending